Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab brengitecan + pertuzumab
- Development stage
- Phase 3
- Lead developer
- Biokin Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
T-Bren + pertuzumab is an investigational combination therapy consisting of trastuzumab brengitecan (T-Bren; BL-M07D1), a HER2-directed antibody-drug conjugate (ADC), and pertuzumab, a HER2-targeting monoclonal antibody. Trastuzumab brengitecan comprises a humanized anti-HER2 monoclonal antibody conjugated via a cathepsin B-cleavable linker to Ed-04, a potent topoisomerase I inhibitor payload (a camptothecin derivative), with a drug-to-antibody ratio (DAR) of 8. Pertuzumab is a recombinant humanized monoclonal antibody that binds to extracellular domain II of HER2, preventing HER2 from heterodimerizing with other HER receptors (such as HER3). The combination is being evaluated in clinical trials, including a Phase 3 trial (NCT07518173) for first-line HER2-positive recurrent or metastatic breast cancer and a Phase 2/3 trial (NCT06891833) as neoadjuvant therapy for HER2-positive breast cancer.
- Other names
- T-Bren + pertuzumab
02
Targets
CTSB (Cathepsin B)TOP1 (DNA Topoisomerase I)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on trastuzumab brengitecan + pertuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab brengitecan + pertuzumab.